

# **A Multicenter, Prospective, Observational Study to Determine Association of Mesangial C1q Deposition with Renal Outcomes in IgA Nephropathy**

Li Tan, MD <sup>1,5,6</sup>, Yi Tang, MD <sup>1</sup>, Gaiqin Pei, MD <sup>1,6</sup>, Zhengxia Zhong, MD <sup>2,6</sup>, Jiaxing Tan, MD <sup>1,6</sup>, Ling Zhou, MD <sup>3,6</sup>, Dongmei Wen, MD <sup>4,6</sup>, David Sheikh-Hamad, MD <sup>5</sup>, Wei Qin, MD <sup>1</sup>

<sup>1</sup> Division of Nephrology, Department of Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

<sup>2</sup> Division of Nephrology, Department of Medicine, Affiliated Hospital of Zunyi Medical University, Medical University, Zunyi, Guizhou, China.

<sup>3</sup> Division of Nephrology, Zigong Third People's Hospital, Zigong, Sichuan, China.

<sup>4</sup> Division of Nephrology, People's Hospital of Jianyang, Chengdu, Sichuan, China.

<sup>5</sup> Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.

<sup>6</sup> West China School of Medicine, Sichuan University, Chengdu, Sichuan, China.

Correspondence to: Wei Qin, Division of Nephrology, Department of Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Tel. 86-28-85422338, Fax +86-028-8542-3341. Email qinweihx@scu.edu.cn.

**TableS1. Demographic and Clinical Features of IgAN Patients.**

Characteristics	Groups					
	All (n=1071)	C1q-positive (n = 145)	Unmatched cohort C1q-negative (n=926)	P value	Matched Cohort (1:1 PSM) C1q-negative (n=145)	P value
<b>Clinical</b>						
Age (year)	33.80 ± 10.96	33.18 ± 10.94	33.89 ± 10.97	0.466	34.05 ± 11.74	0.409
Male (%)	464 (43.32)	57 (39.31)	407 (43.95)	0.290	57 (39.31)	0.962
SBP (mmHg)	130.63 ± 20.27	133.50 ± 21.36	130.18 ± 20.07	0.066	131.89 ± 21.58	0.167
DBP (mmHg)	83.58 ± 14.21	85.78 ± 14.92	83.24 ± 14.07	0.045	82.65 ± 14.61	0.153
MAP (mmHg)	99.26 ± 15.35	101.69 ± 16.45	98.88 ± 15.14	0.041	99.06 ± 16.08	0.143
Hypertension (%)	374 (34.92)	58 (40.00)	316 (34.13)	0.168	51 (35.17)	0.422
Serum creatinine (μmol/L)	100.76 ± 53.06	107.60 ± 53.70	99.69 ± 52.90	0.095	100.91 ± 54.89	0.296
eGFR (ml/min per 1.73 m <sup>2</sup> )	87.48 ± 49.72	81.03 ± 34.84	88.49 ± 51.60	0.027	87.12 ± 34.27	0.043
Urinary protein (g/24h)	2.67 ± 2.99	3.27 ± 2.74	2.58 ± 3.02	0.010	2.58 ± 2.47	0.026
Serum albumin (g/L)	38.15 ± 12.51	35.90 ± 7.96	38.50 ± 13.05	0.020	37.94 ± 6.95	0.021
Uric acid (μmol/L)	378.79 ± 158.08	377.05 ± 106.72	379.06 ± 164.72	0.887	371.92 ± 109.58	0.812
CKD stage				0.049		0.399
Stage 1	531 (49.58)	63 (43.45)	468 (50.54)		68 (46.90)	
Stage 2	267 (24.93)	32 (22.07)	235 (25.38)		40 (27.59)	
Stage 3	219 (20.45)	42 (28.97)	177 (19.11)		31 (21.38)	
Stage 4	54 (5.04)	8 (5.52)	46 (4.97)		6 (4.14)	
Treatment				0.043		0.972
SC	411 (38.38)	42 (28.97)	369 (39.85)		42 (28.97)	
CS	390 (36.41)	61 (42.07)	329 (35.53)		61 (42.07)	
IT	270 (25.21)	42 (28.97)	228 (24.62)		42 (28.97)	

*Note:* Values for categorical variables are given as number (percentage); values for continuous variables are given as mean ± standard deviation or median (interquartile range). Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; SC, supportive care group; CS, corticosteroids; IT, immunosuppressive therapy.